Treace Medical Concepts, a medical technology company specializing in surgical treatments for bunions and foot conditions, announced it will present at the Stifel 2026 Healthcare Conference on November 11, 2026. The company is known for its patented Lapiplasty 3D Bunion Correction System and other innovative surgical products addressing foot deformities. This presentation provides an opportunity for investors to learn about Treace's latest advancements and market expansion strategies. A live webcast will be available on Treace's investor relations website.
Treace Medical Concepts' upcoming presentation at the Stifel 2026 Healthcare Conference offers context for healthcare sector investors. For readers following healthcare stocks, 92 of 150 priced US health-sector stocks on Pluang rose while 55 fell as of Nov 04, 2026 04:11 WIB. Notable movers include Revvity Inc at USD 164.46 with a 1-day change of +8.45% and 100% buy order activity, Twist Bioscience Corp at USD 139.50 with +8.11%, and GeneDx Holdings Corp at USD 68.89 with +7.49%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
